Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs

Journal of the American Veterinary Medical Association

Volumn 209, Issue 12, 1996, Pages 2073-2075

  Krawiec, Donald R ^a   McKiernan, Brendan C ^a   Twardock, A Robert ^a   Swenson, Christine E ^b   Itkin, Randall J ^c,d   Johnson, Lynelle R ^c   Kurowsky, Lisa K ^a   Marks, Carol A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Liposome Company Incorporated   (United States)

^c University of Missouri ^*

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ARTICLE; BLASTOMYCOSIS; DOG; DRUG EFFICACY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; NONHUMAN; RELAPSE;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BLASTOMYCOSIS; DOG DISEASES; DOGS; DRUG CARRIERS; DRUG COMBINATIONS; FEMALE; GLOMERULAR FILTRATION RATE; KIDNEY; LIPOSOMES; MALE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 0029955392     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Wolf AM, Troy GC. Deep mycotic diseases. In: Ettinger SJ. ed. Textbook of veterinary internal medicine. Philadelphia: WB Saunders Co, 1989;341-371.
2. Legendre AM, Selcer BA, Edwards DF, et al. Treatment of canine blastomycosis with amphotericin B and ketoconazole. J Am Vet Med Assoc 1984;184:1249-1254.
3. Rubin SI, Krawiec DR, Gelberg H, et al. Nephrotoxicity of amphotericin B in dogs: a comparison of two methods of administration. Can J Vet Res 1989;53:23-28.
4. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995;6:154-164.
5. Szoka FC Jr, Tang M. Amphotericin B formulated in liposomes and lipid based systems: a review. J Liposome Res 1993;3:363-375.
6. Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994;33:907-916.
7. Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A 1988;85:6122-6126.
8. Janoff AS, Perkins WR, Saletan SL, et al. Amphotericin B lipid complex (ABLC®): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993;3:451-471.
9. Clark JM, Whitney RR, Olsen SJ, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991;35:615-621.
10. Perfect JR, Wright KA. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 1994;33:73-81.
11. Clemons KV, Stevens DA. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J Antimicrob Chemother 1992;30:353-363.
12. Clemons KV, Stevens DA. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991;35:2144-2146.